Lonza Expands Drug Product Services in Switzerland

Investment in Stein

Lonza is investing in a new aseptic flexible filling line for clinical drug product supply in Stein, Switzerland. This line will handle liquid and lyophilized vial filling, cartridges, and pre-filled syringes. It will support various modalities, including monoclonal antibodies, bioconjugates, viral vectors, and gene therapy products. The installation, featuring state-of-the-art robotic and freeze-drying technology, is expected to be completed in 2023 and will create over 70 new positions.

Expansion in Basel

To support the global increase in drug product capacity, Lonza is also expanding its Drug Product Services (DPS) for parenteral dosage forms in Basel. This expansion will enhance pharmaceutical development for early and late clinical stages and increase process development and characterization capabilities. The new DPS facilities in Basel are expected to be operational in 2024.

Complementary Capacity in Visp

The additional flexible filling line and the expansion of DPS will complement the drug product manufacturing capacity at Lonza's Visp site, which is expected to come online in the first half of 2022. This site, part of the Ibex® Solutions biopark, will support aseptic drug product manufacturing and filling of liquid and lyophilized vials.

Global Expansion

Since introducing drug product development and manufacturing services in 2016, Lonza has expanded its capabilities in Basel, Stein, and Guangzhou, China. This new investment brings Lonza's global drug product manufacturing and fill and finish capacity to three sites, including four vial lines and one flexible filling line.